An Enzyme-Linked Immunosorbent Assay to Study Bevacizumab Pharmacokinetics

Magdelaine-Beuzelin, 2007, Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment., Crit Rev Oncol Hematol, 64, 210, 10.1016/j.critrevonc.2007.04.011

Kim, 1993, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo., Nature, 362, 841, 10.1038/362841a0

Ferrara, 2003, The biology of VEGF and its receptors., Nat Med, 9, 669, 10.1038/nm0603-669

Gerber, 2005, Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies., Cancer Res, 65, 671, 10.1158/0008-5472.671.65.3

Miller, 2007, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer., N Engl J Med, 357, 2666, 10.1056/NEJMoa072113

Sandler, 2006, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer., N Engl J Med, 355, 2542, 10.1056/NEJMoa061884

Ainsworth, 2009, Impact of anti-angiogenic treatments on metastatic renal cell carcinoma., Expert Rev Anticancer Ther, 9, 1793, 10.1586/era.09.144

Tong, 2004, Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors., Cancer Res, 64, 3731, 10.1158/0008-5472.CAN-04-0074

Herbst, 2005, Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer., J Clin Oncol, 23, 2544, 10.1200/JCO.2005.02.477

Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer., N Engl J Med, 350, 2335, 10.1056/NEJMoa032691

Yang, 2003, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer., N Engl J Med, 349, 427, 10.1056/NEJMoa021491

Gordon, 2009, A review on bevacizumab and surgical wound healing: an important warning to all surgeons., Ann Plast Surg, 62, 707, 10.1097/SAP.0b013e3181828141

Gordon, 2001, Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer., J Clin Oncol, 19, 843, 10.1200/JCO.2001.19.3.843

Lu, 2008, Clinical pharmacokinetics of bevacizumab in patients with solid tumors., Cancer Chemother Pharmacol, 62, 779, 10.1007/s00280-007-0664-8

Delbaldo, 2005, Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma., Eur J Cancer, 41, 1739, 10.1016/j.ejca.2005.04.029

Margolin, 2001, Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data., J Clin Oncol, 19, 851, 10.1200/JCO.2001.19.3.851